Category: Federal Forum Posters
Purpose: Glucocorticoid-induced osteoporosis (GIOP) is one of the most common causes of secondary osteoporosis. Current research shows the proportion of patients being treated with long-term glucocorticoids who are receiving osteoporosis-preventing treatments remains low. The 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis outlines specific recommendations in terms of risk fracture assessments with FRAX and BMD evaluation, as well as recommendations for pharmacologic management. An evaluation of the implementation of these new guidelines into practice is needed.
Methods: This study will be a retrospective chart review of adult patients on long-term prednisone therapy (defined as greater than or equal to three months). A report will be generated to include all patients prescribed prednisone during the last two years. Patient profiles will be manually reviewed and evaluated to ensure inclusion criteria for analysis is met. Data will be collected and analyzed on patient age, gender, ethnicity, osteoporosis risk factors, fracture risk and history, FRAX score, BMD T-score, medication-specific information (fill history, dose, length of therapy) for all medications of interest, medication side effects, contraindications to therapy, liver function, and renal function. Further review will be done to assess if provider education previously done by a Clinical Pharmacy Specialist increases adherence to the recommendations.
Results: not applicable
Conclusion: not applicable
Catrina Hill– PGY1 Pharmacy Resident, Atlanta VA Health Care System, Loganville, GA